BC
RNAM

Bridgefront Capital’s Avidity Biosciences RNAM Stock Holding History

Bridgefront Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,485
Closed -$293K – 633
2024
Q1 		$293K Buy
+11,485
New +$180K 0.22% 190

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bridgefront Capital's RNAM Position: Q2 2024 in Review

Bridgefront Capital sold out of Avidity Biosciences (RNAM) in Q2 2024, closing a stake of 11,485 shares — an estimated $293K sold.

Bridgefront Capital first reported a position in RNAM in Q1 2024 and held it in 1 quarter. The position peaked at $293K in Q1 2024. 196 funds tracked by Wall St. Rank hold RNAM as of Q2 2024.

  • Bridgefront Capital reported no remaining Avidity Biosciences position as of Q2 2024 after selling out during the quarter.
  • Bridgefront Capital sold 11,485 Avidity Biosciences shares in Q2 2024, an estimated $293K.
  • Bridgefront Capital first reported a position in Avidity Biosciences in Q1 2024 and held it in 1 quarter.
  • Bridgefront Capital's Avidity Biosciences position peaked at $293K in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2024.

Based on Bridgefront Capital's 13F filing for Q2 2024, filed 14 Aug 2024.